Humana (NYSE:HUM) Downgraded by Zacks Research to “Hold”

Humana (NYSE:HUM) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Humana’s Q1 2027 earnings at $9.04 EPS.

Other research analysts also recently issued research reports about the stock. Seaport Research Partners downgraded shares of Humana to a “neutral” rating in a research report on Wednesday, May 20th. Morgan Stanley raised Humana from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $249.00 to $370.00 in a report on Tuesday, August 4th. HSBC cut Humana to a “hold” rating in a research report on Thursday, July 30th. Lake Street Capital started coverage on shares of Humana in a research report on Thursday, July 30th. They set a “buy” rating for the company. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $425.00 price objective on shares of Humana in a research note on Wednesday, June 3rd. Fourteen analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $395.22.

Humana Stock Performance

HUM opened at $388.86 on Tuesday. The firm has a market capitalization of $46.69 billion, a P/E ratio of 36.79, a price-to-earnings-growth ratio of 2.13 and a beta of 0.72. The stock’s 50 day moving average price is $380.56 and its two-hundred day moving average price is $274.05. Humana has a 12-month low of $163.11 and a 12-month high of $428.88. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.Humana’s revenue for the quarter was up 26.2% on a year-over-year basis. During the same period in the prior year, the company earned $6.27 EPS. On average, equities analysts forecast that Humana will post 9.09 earnings per share for the current year.

Institutional Trading of Humana

Several large investors have recently made changes to their positions in the company. Montag A & Associates Inc. boosted its holdings in Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Humana during the second quarter valued at approximately $26,000. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana during the fourth quarter valued at approximately $27,000. Trust Co. of Vermont acquired a new position in shares of Humana during the second quarter worth approximately $28,000. Finally, Reflection Asset Management acquired a new position in shares of Humana during the fourth quarter worth approximately $29,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.